Effect of Covid-19 vaccine on some immunological salivary biomarkers (sIgA and Interleukine-17)

Dhuha M.  Ali; Ghada I.  Taha

doi:10.32007/jfacmedbagdad.2039

Authors

Dhuha M. Ali Dept. of Basic Science in Oral Microbiology, College of Dentistry, University of Baghdad, Baghdad, Iraq. https://orcid.org/0000-0001-7314-1427
Ghada I. Taha Dept. of Basic Science in Oral Microbiology, College of Dentistry, University of Baghdad, Baghdad, Iraq. https://orcid.org/0000-0002-1958-1939

DOI:

https://doi.org/10.32007/jfacmedbagdad.2039

Keywords:

SARS-CoV-2, , Covid-19,, Vaccination, Pfizer (BNT162b2), Secretory (sIgA), IL-17.

Abstract

Background: The most widely used vaccination against SARS-associated coronavirus (SARS-CoV-2) is the Pfizer vaccine, which provides protection against this virus. However, its ability to safeguard the oral cavity is unclear, and neither are the exact immunological biomarker levels it activates.

Aim of the study: To investigate the possibility that Pfizer vaccination protects the oral cavity against Covid-19.

Patients and Methods: The study group consisted of a total of 70 subjects (30 as the control group They were followed up before being vaccinated as non-vaccinated (maybe previously infected or non-infected or recovered) and 40 participants followed up three weeks after the first dose and one week after the second vaccination. All saliva samples were collected from the individuals in the current study at the medical city hospital in Baghdad from September 2021 to July 2022. The salivary biomarkers sIgA and IL-17 were detected by enzyme-linked immunosorbent assay (ELISA) kits.

Result: Secretory IgA levels showed a highly significant difference (p0.05) in the followed-up group after the first vaccination compared to the non-vaccinated group (controls), however, a non-significant difference in its level was found in the followed-up group after the first vaccination compared to after the second vaccination. In contrast to healthy controls, non-vaccinated participants had greater salivary IL-17 levels. Followed-up participants’ IL-17 levels did not change significantly after the first and second vaccines (P>0.05).

Conclusion: The Pfizer vaccine had a minor impact on sIgA because mRNA vaccines protect systemically more than salivary. Nevertheless, the Pfizer vaccine raises IL-17 levels after the first and second doses without triggering cytokine syndrome.

Received: Dec. 2022
Accepted: May, 2023
Published: July.2023

Downloads

Download data is not yet available.

Author Biography

Ghada I. Taha, Dept. of Basic Science in Oral Microbiology, College of Dentistry, University of Baghdad, Baghdad, Iraq.

بكالوريوس ، ماجستير ، دكتوراه ، علم الأحياء الدقيقة / المناعة السريرية.
أستاذ مساعد ، قسم العلوم الأساسية في ميكروبيولوجيا الفم ، كلية طب الأسنان ، جامعة بغداد.

References

Nejabi M, Noor N, Raufi N, Essar M, Ehsan E, Shah J, et al. Tongue ulcer in a patient with COVID-19: a case presentation. BMC Oral Health 2021;21:1-5. https://doi.org/10.1186/s12903-021-01635-8

Farook FF, Nuzaim MNM, Ababneh KT, Alshammari A & Alkadi L. COVID-19 pandemic: Oral health challenges and recommendations European journal of dentistry. 2020; 14(S 01), S165-S170. https://doi.org/10.1055/s-0040-1718641

Sauer K, & Harris T. An effective COVID-19 vaccine needs to engage T cells Frontiers in Immunology. 2020; 2371.

https://doi.org/10.3389/fimmu.2020.581807

Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB & Prado EO. SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates npj Vaccines. 2021; 6(1), 1-17. https://doi.org/10.1038/s41541-021-00292-w

Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Antibodies to combat viral infections: development strategies and progress Nature Reviews Drug Discovery. 2022; 21(9), 676-696ز https://doi.org/10.1038/s41573-022-00495-3

Al-Atrooshi BA, Al-Rawi AS. 2007. Oral halitosis and oral hygiene practices among dental students. Journal of Baghdad college of dentistry; 19(1), 72-76.

Rashad S, El-Chaghaby G. Algae Bioactive Constituents and Possible Role During COVID-19 Pandemic (A review) Iraqi Journal of Pharmaceutical Sciences (P-ISSN: 1683-3597, E-ISSN: 2521-3512). 2021; 30(2), 16-22‏ https://doiorg/1031351/vol30iss2pp16-22.

https://doi.org/10.31351/vol30iss2pp16-22

Khamees SI & Mohammad AN. Evaluation of inorganic ions and enzymes levels in saliva of patients with chronic periodontitis and healthy subjects. Therapy. 2012; 6, 7.

Khanday AMUD, Khan QR, Rabani ST. Ensemble Approach for Detecting COVID-19 Propaganda on Online Social Networks Iraqi Journal of Science. 2022; 63(10), 4488-4498 https://doiorg/1024996/ijs2022631033. https://doi.org/10.24996/ijs.2022.63.10.33

Al-Azzawi AKJ and Al-Zubaidi, AK. 2014. The effect of various endodontic irrigants on the sealing ability of biodentine and other root perforation repair materials: in vitro study. J. Baghdad Coll. Dent; 26, 1-8. https://doi.org/10.12816/0015217

Adham ZS, & Al-Ghurabi BH. Prevalence of viral co-infection among COVID-19 cases in association disease severity and oral hygiene Journal of Baghdad College of Dentistry. 2021; 33(3), 1-8https://doiorg/1026477/jbcdv33i32947.

https://doi.org/10.26477/jbcd.v33i3.2947

Matuchansky C. Mucosal immunity to SARS-CoV-2: a clinically relevant key to deciphering natural and vaccine-induced defences Clinical Microbiology and Infection, 2021; 27(12), 1724-1726. https://doi.org/10.1016/j.cmi.2021.08.008

Isaza-Guzmán DM, Cardona-Vélez N, Gaviria-Correa DE, Martínez-Pabón MC, Castaño-Granada MC, Tobón-Arroyave SI. Association study between salivary levels of interferon (IFN)-gamma, interleukin (IL)-17, IL-21, and IL-22 with chronic periodontitis Archives of oral biology. 2015; 60(1), 91-99. https://doi.org/10.1016/j.archoralbio.2014.09.002

Mills KH. IL-17 and IL-17-producing cells in protection versus pathology Nature Reviews Immunology. 2022; 1-17.

https://doi.org/10.1038/s41577-022-00746-9ز 15. Shibabaw T. Inflammatory cytokine: IL-17A signaling pathway in patients present with COVID-19 and current treatment strategy Journal of inflammation research. 2020; 13, 673. https://doi.org/10.2147/JIR.S278335

Kareem HH, Al-Ghurabi BH, Albadri C. Molecular Detection of Porphyromonas gingivalis in COVID-19 Patients Journal of Baghdad College of Dentistry. 2022; 34(2), 52-61. https://doi.org/10.26477/jbcd.v34i2.3145

Kar S, Devnath P, Emran TB, Tallei TE, Mitra S, Dhama K. Oral and intranasal vaccines against SARS‐CoV‐2: Current progress, prospects, advantages, and challenges Immunity, Inflammation and Disease. 2022; 10(4), e604.

https://doi.org/10.1002/iid3.604

Hassan RT, Mohammed SH.. Evaluation of immunoglobulin G level among subjects vaccinated with different types of COVID-19 vaccines in the karbala population, Iraq. Biomedical and Biotechnology Research Journal (BBRJ,2022; 6(3), 466.‏

https://doi.org/10.4103/bbrj.bbrj_213_22

Tu MK, Chiang SH, Bender RA, Wong DT, Strom CM. The kinetics of COVID-19 vaccine response in a community-vaccinated population The Journal of Immunology. 2022; 208(4), 819-826. https://doi.org/10.4049/jimmunol.2100919

Al-dulaimi AA, Al-Issa YA. Comparison between the Impact of Pfizer Vaccination and Covid-19 Infection on Human Creatine Kinase Activity and its Isoenzymes. The Egyptian Journal of Hospital Medicine, 2023; 90(1), 1923-1927.‏

https://doi.org/10.21608/ejhm.2023.284763

Tsukinoki K, Yamamoto T, Handa K, Iwamiya M, Saruta J, Ino S, et al. Detection of cross-reactive immunoglobulin A against the severe acute respiratory syndrome-coronavirus-2 spike 1 subunit in saliva PloS one. 2021; 16(11), e0249979.

https://doi.org/10.1371/journal.pone.0249979

Rasheed AM, Fatak DF, Hashim HA, Maulood M F, Kabah KK, Almusawi Y. A., Abdulamir A S. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med, 2020; 28(3), 357-366. https://doi.org/10.1101/2020.06.24.20121905

Estadilla CDS, Uyheng J, de Lara-Tuprio EP, Teng TR, Macalalag JMR, Estuar MRJE. Impact of vaccine supplies and delays on optimal control of the COVID-19 pandemic: mapping interventions for the Philippines Infectious Diseases of Poverty. 2021; 10(04), 46-59.

https://doi.org/10.1186/s40249-021-00886-5

Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in hospitalized patients with COVID-19 Journal of the American Society of Nephrology. 2021; 32(1), 151-160.

Jensen A, Stromme M, Moyassari S, Chadha AS, Tartaglia MC, Szoeke C, et al. COVID-19 vaccines: Considering sex differences in efficacy and safety Contemporary Clinical Trials. 2022; 106700. https://doi.org/10.1016/j.cct.2022.106700

Mahmood Z S, Fadhil HY., Ad AH. Estimation of hematological parameters of disease severity in Iraqi patients with COVID-19. Iraqi Journal of Science, 2021; 3487-3496. https://doi.org/10.24996/ijs.2021.62.10.8

Darwich A, Pozzi C, Fornasa G, Lizier M, Azzolini E, Spadoni I, et al. BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? EMBO molecular medicine. 2022; 14(5), e15326. https://doi.org/10.15252/emmm.202115326

Sheikh-Mohamed S, Isho B, Chao GY, Zuo M, Cohen C, Lustig Y, et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection Mucosal immunology. 2022; 1-10. https://doi.org/10.1038/s41385-022-00511-0

Mohamed SS, Chao GY, Isho B, Zuo M, Nahass GR, Salomon-Shulman R E, et al. A mucosal antibody response is induced by intra-muscular SARS-CoV-2 mRNA vaccination medRxiv. 2021.

Sano, K., Bhavsar, D., Singh, G., Floda, D., Srivastava, K., Gleason, C., ... & Krammer, F. (2022). SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. Nature Communications. 13(1); 5135.

https://doi.org/10.1038/s41467-022-32389-8

Sundar S, Ramadoss, R., Shanmugham, R, Ananda padmanabhan LT, Paneerselvam S, Ramani P & Karobari MI. 2022. Salivary Antibody Response of COVID-19 in Vaccinated and Unvaccinated Young Adult Populations. Vaccines. 10(11); 1819.

https://doi.org/10.3390/vaccines10111819

Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China Clinical immunology. 2020; 214, 108393.

https://doi.org/10.1016/j.clim.2020.108393

Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. (2021, June) Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients In Open forum infectious diseases. 2021; (Vol 8, No 6, p ofab156) US: Oxford University Press. https://doi.org/10.1093/ofid/ofab156

Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Journal of virology. 2011, 85(23), 12201-12215. https://doi.org/10.1128/JVI.06048-11

Kimura A & Kishimoto T. IL‐6: regulator of Treg/Th17 balance European journal of immunology. 2010; 40(7), 1830-1835

https://doi.org/10.1002/eji.201040391

Rokni M, Hamblin MR, Rezaei N. Cytokines and COVID-19: friends or foes? Human vaccines & immunotherapeutics. 2020; 16(10), 2363-2365. https://doi.org/10.1080/21645515.2020.1799669

Jin W & Dong C. IL-17 cytokines in immunity and inflammation Emerging microbes & infections. 2013; 2(1), 1-5.

https://doi.org/10.1038/emi.2013.58

Martonik D, Parfieniuk-Kowerda A, Rogalska M, Flisiak R. The role of Th17 response in COVID-19 Cells. 2021; 10(6), 1550.

https://doi.org/10.3390/cells10061550

Lin Y, Slight SR, & Khader SA (2010, March) Th17 cytokines and vaccine-induced immunity In Seminars in immunopathology (Vol 32, No 1, pp 79-90) Springer-Verlagز https://doi.org/10.1007/s00281-009-0191-2

Merino KM, Jazwinski SM, Rout N. Th17-type immunity and inflammation of aging Aging (Albany NY). 2021; 13(10), 13378.

https://doi.org/10.18632/aging.203119